PURPOSE: The purpose of this trial was to evaluate the role of radiation therapy with concurrent gemcitabine (GEM) compared with GEM alone in patients with localized unresectable pancreatic cancer. PATIENTS AND METHODS: Patients with localized unresectable adenocarcinoma of the pancreas were randomly assigned to receive GEM alone (at 1,000 mg/m(2)/wk for weeks 1 to 6, followed by 1 week rest, then for 3 of 4 weeks) or GEM (600 mg/m(2)/wk for weeks 1 to 5, then 4 weeks later 1,000 mg/m(2) for 3 of 4 weeks) plus radiotherapy (starting on day 1, 1.8 Gy/Fx for total of 50.4 Gy). Measurement of quality of life using the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire was also performed. RESULTS: Of 74 patients entered on trial and randomly assigned to receive GEM alone (arm A; n = 37) or GEM plus radiation (arm B; n = 34), patients in arm B had greater incidence of grades 4 and 5 toxicities (41% v 9%), but grades 3 and 4 toxicities combined were similar (77% in A v 79% in B). No statistical differences were seen in quality of life measurements at 6, 15 to 16, and 36 weeks. The primary end point was survival, which was 9.2 months (95% CI, 7.9 to 11.4 months) and 11.1 months (95% CI, 7.6 to 15.5 months) for arms A and B, respectively (one-sided P = .017 by stratified log-rank test). CONCLUSION: This trial demonstrates improved overall survival with the addition of radiation therapy to GEM in patients with localized unresectable pancreatic cancer, with acceptable toxicity.
RCT Entities:
PURPOSE: The purpose of this trial was to evaluate the role of radiation therapy with concurrent gemcitabine (GEM) compared with GEM alone in patients with localized unresectable pancreatic cancer. PATIENTS AND METHODS: Patients with localized unresectable adenocarcinoma of the pancreas were randomly assigned to receive GEM alone (at 1,000 mg/m(2)/wk for weeks 1 to 6, followed by 1 week rest, then for 3 of 4 weeks) or GEM (600 mg/m(2)/wk for weeks 1 to 5, then 4 weeks later 1,000 mg/m(2) for 3 of 4 weeks) plus radiotherapy (starting on day 1, 1.8 Gy/Fx for total of 50.4 Gy). Measurement of quality of life using the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire was also performed. RESULTS: Of 74 patients entered on trial and randomly assigned to receive GEM alone (arm A; n = 37) or GEM plus radiation (arm B; n = 34), patients in arm B had greater incidence of grades 4 and 5 toxicities (41% v 9%), but grades 3 and 4 toxicities combined were similar (77% in A v 79% in B). No statistical differences were seen in quality of life measurements at 6, 15 to 16, and 36 weeks. The primary end point was survival, which was 9.2 months (95% CI, 7.9 to 11.4 months) and 11.1 months (95% CI, 7.6 to 15.5 months) for arms A and B, respectively (one-sided P = .017 by stratified log-rank test). CONCLUSION: This trial demonstrates improved overall survival with the addition of radiation therapy to GEM in patients with localized unresectable pancreatic cancer, with acceptable toxicity.
Authors: R A Wolff; D B Evans; D M Gravel; R Lenzi; P W Pisters; J E Lee; N A Janjan; C Charnsangavej; J L Abbruzzese Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531
Authors: A W Blackstock; S A Bernard; F Richards; K S Eagle; L D Case; M E Poole; P D Savage; J E Tepper Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Higinia R Cardenes; Annette M Moore; Cynthia S Johnson; Menggang Yu; Paul Helft; Elena G Chiorean; Jacob Vinson; Thomas J Howard; Anthony W Stephens; D Fritz Tai; Patrick J Loehrer Journal: Am J Clin Oncol Date: 2011-10 Impact factor: 2.339
Authors: M S Talamonti; P J Catalano; D J Vaughn; R Whittington; R D Beauchamp; J Berlin; A B Benson Journal: J Clin Oncol Date: 2000-10-01 Impact factor: 44.544
Authors: G V Kornek; R Pötter; E Selzer; A Schratter; H Ulrich-Pur; M Rogy; G Kraus; W Scheithauer Journal: Int J Radiat Oncol Biol Phys Date: 2001-03-01 Impact factor: 7.038
Authors: A Duffy; J Kortmansky; G K Schwartz; M Capanu; S Puleio; B Minsky; L Saltz; D P Kelsen; E M O'Reilly Journal: Ann Oncol Date: 2007-09-17 Impact factor: 32.976
Authors: B Chauffert; F Mornex; F Bonnetain; P Rougier; C Mariette; O Bouché; J F Bosset; T Aparicio; L Mineur; A Azzedine; P Hammel; J Butel; N Stremsdoerfer; P Maingon; L Bedenne Journal: Ann Oncol Date: 2008-05-07 Impact factor: 32.976
Authors: Elizabeth Poplin; Yang Feng; Jordan Berlin; Mace L Rothenberg; Howard Hochster; Edith Mitchell; Steven Alberts; Peter O'Dwyer; Daniel Haller; Paul Catalano; David Cella; Al Bowen Benson Journal: J Clin Oncol Date: 2009-07-06 Impact factor: 44.544
Authors: D Goldstein; G Van Hazel; E Walpole; C Underhill; D Kotasek; M Michael; J Shapiro; T Davies; W Reece; J Harvey; N Spry Journal: Br J Cancer Date: 2007-07-24 Impact factor: 7.640
Authors: Md Faiz Ahmad; Intekhab Alam; Sarah E Huff; John Pink; Sheryl A Flanagan; Donna Shewach; Tessianna A Misko; Nancy L Oleinick; William E Harte; Rajesh Viswanathan; Michael E Harris; Chris Godfrey Dealwis Journal: Proc Natl Acad Sci U S A Date: 2017-07-17 Impact factor: 11.205
Authors: Jonathan B Ashman; Adyr A Moss; William G Rule; Matthew G Callister; K Sudhakar Reddy; David C Mulligan; Joseph M Collins; Giovanni De Petris; Leonard L Gunderson; Mitesh Borad Journal: J Gastrointest Oncol Date: 2013-12
Authors: Agata I Rembielak; Pooja Jain; Andrew S Jackson; Melanie M Green; Gillian R Santorelli; Gillian A Whitfield; Adrian Crellin; Angel Garcia-Alonso; Ganesh Radhakrishna; James Cullen; M Ben Taylor; Ric Swindell; Catharine M West; Juan Valle; Azeem Saleem; Patricia M Price Journal: Transl Oncol Date: 2014-02-01 Impact factor: 4.243